DexCom, Inc. (NASDAQ:DXCM) EVP Sells $181,641.90 in Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

DexCom Stock Performance

NASDAQ:DXCM opened at $87.62 on Friday. The firm has a 50-day moving average of $80.22 and a two-hundred day moving average of $76.59. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The stock has a market cap of $34.22 billion, a P/E ratio of 52.47, a PEG ratio of 2.23 and a beta of 1.12. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

Analyst Upgrades and Downgrades

Several brokerages recently commented on DXCM. Citigroup upped their price target on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Royal Bank of Canada cut their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Wells Fargo & Company boosted their price target on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Oppenheimer decreased their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $99.29.

Hedge Funds Weigh In On DexCom

A number of hedge funds have recently bought and sold shares of the company. Blue Whale Capital LLP lifted its stake in DexCom by 91.9% during the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after purchasing an additional 113,000 shares during the last quarter. Taylor Frigon Capital Management LLC lifted its position in shares of DexCom by 51.6% in the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after buying an additional 11,075 shares during the last quarter. Brooktree Capital Management bought a new position in shares of DexCom in the 3rd quarter worth about $683,000. National Pension Service boosted its holdings in shares of DexCom by 4.1% in the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after buying an additional 37,363 shares during the period. Finally, Intact Investment Management Inc. bought a new stake in shares of DexCom during the 3rd quarter valued at about $650,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.